The Relation Between Fecal Calprotectin and the Rate of Clinical Activity of Ulcerative Colitis

Document Type : Original Article

Authors

¹ Associate Professor, Gastroenterology and Hepatology,Mashhad University of Medical Sciences,Mashhad, Iran

² Gastroenterology and Hepatology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

³ Assistant Professor, Gastroenterology and Hepatology, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁴ Assistant Professor of Microbiology, Sabzevar University of Medical Sciences, Sabzevar, Iran

⁵ Assistant Professor, Gastroenterology, Department of Internal Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran

⁶ Assistant Professor, Gastroenterology and Hepatology, Mashhad University of Medical Sciences, Mashhad, Iran

⁷ Corresponding a

10.30483/RIJM.2018.68

Abstract

Background: Inflammatory bowel disease is a disorder with unknown origin in which environment, genetics, and immunity play a part. Although colonoscopy and biopsy are expensive and invasive, are used to monitoring the mucosal inflammation. Fecal calprotectin is a non-invasive test which has attracted a lot of attention. We aimed to determine the relation of fecal calprotectin and clinical activity of ulcerative colitis.

Methods: This cross-sectional study took place with the confirmation of ethics committee of Mashhad University of Medical Sciences in 2014 - 2015. Patients with diagnosis of ulcerative colitis were included; demographic information was recorded and clinical activity of disease was evaluated. Fecal calprotectin was measured by the quantitative ELISA method and results of laboratory studies and clinical examinations were analyzed by SPSS software version 16. Level of significance was considered less than 0.05.

Results: Seventy patients were studied (male = 56%, average age = 38 15). 25 patients (36.2%) were newly diagnosed. The average period of disease was 4.1 ± 5 years. 25 individuals (35.7%) had mild, 19 individuals (27.1%) had moderate, and 26 individuals (37.1%) had severe disease. Averages of fecal calprotectin in mild, moderate, and severe disease were 132 111, 119 44 and 141 78 g/ g, respectively. Averages of fecal calprotectin in mild and moderate disease (P = 0.874), in mild and severe (P = 0.925) and in moderate and severe disease (P = 0.662) were not significantly different.

Conclusions: Although fecal calprotectin in severe ulcerative colitis is higher, it has no relation with disease clinical activity.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1.Moris G. Inflammatory bowel disease: an increased risk factor for neurologic complications. World J Gastroenterol. 2014;20(5):1228-37. [PubMed: 24574797]. https://doi.org/10.3748/wjg.v20.i5.1228 PMid:24574797 PMCid:PMC3921505

2. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-19. [PubMed: 22914296]. https://doi.org/10.1016/S0140-6736(12)60150-0 PMid:22914296

3. Mosli MH, Feagan BG, Sandborn WJ, D'Haens G, Behling C, Kaplan K, et al. Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices. Inflamm Bowel Dis. 2014;20(3):564-75. [PubMed: 24412993]. https://doi.org/10.1097/01.MIB.0000437986.00190.71 PMid:24412993

4. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444-54. [PubMed: 25732419]. https://doi.org/10.1038/ajg.2015.6 PMid:25732419

5. Marie I, Leroi AM, Menard JF, Levesque H, Quillard M, Ducrotte P. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev. 2015;14(6):547-54. [PubMed: 25661980]. https://doi.org/10.1016/j.autrev.2015.01.018 PMid:25661980

6. Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8(2):197-210. [PubMed: 24345070]. https://doi.org/10.1586/17474124.2014.869476 PMid:24345070

7. Mark F, Lawrence SF, Lawrence JB. Sleisenger and Fordtran's Gastrointestinal and liver disease. Pathophysiology/diagnosis/management. 2. 10th ed. United States of America: Elsevier Saunders; 2016. 2040 p. 8. Mao R, Xiao YL, Gao X, Chen BL, He Y, Yang L, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a metaanalysis of prospective studies. Inflamm Bowel Dis. 2012;18(10):1894-9. [PubMed: 22238138]. https://doi.org/10.1002/ibd.22861 PMid:22238138

8. Bennike TB, Carlsen TG, Ellingsen T, Bonderup OK, Glerup H, Bogsted M, et al. Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. Inflamm Bowel Dis. 2015;21(9):2052-67. [PubMed: 25993694]. https://doi.org/10.1097/MIB.0000000000000460 PMid:25993694 PMCid:PMC4603666

9. Calafat M, Cabre E, Manosa M, Lobaton T, Marin L, Domenech E. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?. Inflamm Bowel Dis. 2015;21(5):1072-6. [PubMed: 25793326]. https://doi.org/10.1097/MIB.0000000000000349 PMid:25793326

10. Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Pena C, Benitez Estevez AJ, et al. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. J Clin Gastroenterol. 2016;50(2):147-51. [PubMed: 25811118]. https://doi.org/10.1097/MCG.0000000000000312 PMid:25811118

11. Andrisani G, Guidi L, Papa A, Armuzzi A. Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2012;16(7):890-901. [PubMed: 22953637].

12. Li Z, Long Y, Bai M, Li J, Feng Z. Neutrophil and Eosinophil Granule Proteins as Potential Biomarkers of Assessing Disease Activity and Severity in Patients With Ulcerative Colitis. J Clin Lab Anal. 2016;30(5):776-8. [PubMed: 27076259]. https://doi.org/10.1002/jcla.21937 PMid:27076259 PMCid:PMC6807036

13. Sandborn WJ, Panes J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016;150(1):96-102. [PubMed: 26376350]. https://doi.org/10.1053/j.gastro.2015.09.001 PMid:26376350

14. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis. 2009;15(12):1851-8. [PubMed: 19462421]. https://doi.org/10.1002/ibd.20986 PMid:19462421

15. Kristensen V, Klepp P, Cvancarova M, Roseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015;9(2):164-9. [PubMed: 25518057]. https://doi.org/10.1093/ecco-jcc/jju015 PMid:25518057

16. Kotze LM, Nisihara RM, Marion SB, Cavassani MF, Kotze PG. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arq Gastroenterol. 2015;52(1):50-4 [PubMed: 26017083]. 4 Razavi Int J Med. 2018; 6(1):e14533. Vosoughinia H et al. https://doi.org/10.1590/S0004-28032015000100011 PMid:26017083

17. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14(1):53-7. [PubMed: 18176961]. https://doi.org/10.3748/wjg.14.53 PMid:18176961 PMCid:PMC2673391

18. Lobaton T, Rodriguez-Moranta F, Lopez A, Sanchez E, RodriguezAlonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19(5):1034-42. [PubMed: 23470502]. https://doi.org/10.1097/MIB.0b013e3182802b6e PMid:23470502

Razavi International Journal of Medicine

Volume 6, Issue 1
January 2018
Pages 31-35

Files

Share

How to cite

Statistics

Article View: 137
PDF Download: 104